Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a…
News
Molecular Templates’ Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs
Presentations on the MT-6402 (PD-L1) and MT-5111(HER2) Phase I dose escalation programs demonstrate unique biology,…
Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS),…
Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
ORYZON to Give Updates on Corporate Progress in June
Jefferies Healthcare Conference European Hematology Association Congress, EHA-2022 BIO International Convention LSX World Congress MADRID,…
Reflect Scientific Inc Receives Patent for Green Cooling Technology
OREM, Utah, June 06, 2022 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a provider…
MedMira Receives Patent for its Unique Quantitative Diagnostic System
HALIFAX, Nova Scotia, June 06, 2022 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR)…
Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
Aria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus…
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA…
Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022
PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…
BridgeBio Pharma to Participate in June Investor Events
PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”…
Radius Files Definitive Proxy and Mails Letter to Stockholders
Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman,…
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) — Biogen and…
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator…
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022
YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage…
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO),…
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA…
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying…
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks
RESEARCH TRIANGLE PARK, N.C., June 06, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today…
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
PRESS RELEASE Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal…